Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers
Status:
Completed
Trial end date:
2020-03-13
Target enrollment:
Participant gender:
Summary
Persons who struggle with depression smoke at high rates and experience low quit rates in
treatment. The best way to improve cessation treatment for this underserved population
remains unknown. The proposed trial tests whether the combination of varenicline and
behavioral mood management treatment enhances long-term abstinence for depressed smokers and,
if so, whether this treatment achieves its effects through addressing the unique
psychological factors that appear to maintain tobacco dependence for these smokers.